Related by context. All words. (Click for frequent words.) 80 dose escalation trial 75 Phase Ib 74 Phase 1b 72 Phase 2b trial 72 single ascending dose 72 label dose escalation 71 dose dose escalation 71 multiple ascending dose 71 Phase 1b trial 71 Phase Ib clinical 71 Phase 1b clinical 71 placebo controlled 71 ascending doses 71 Phase 2b study 70 dose escalation 70 dose escalation Phase 70 Phase 2a clinical 70 Phase 2a 69 double blind placebo 69 Phase IIa trial 69 Phase 1a 69 Phase 2a trial 69 randomized placebo controlled 69 ascending dose 69 multicenter Phase 68 Phase IIa clinical 68 Phase IIa 68 Phase 2b clinical 68 Phase IIb clinical 68 multicenter 68 blind randomized placebo 68 dose escalation clinical 68 phase Ib 68 Phase III clinical 68 pivotal Phase III 67 Phase IIb trial 67 safety tolerability pharmacokinetics 67 Phase Ia 67 pharmacokinetics PK 67 randomized Phase III 67 placebo controlled Phase 67 multicenter Phase II 67 clinical trial 67 IIa trial 67 phase 2a 66 placebo controlled clinical 66 phase IIa 66 Phase IIb 66 phase IIb clinical 66 randomized multicenter 66 randomized double 66 phase IIb 66 randomized Phase 66 phase IIa clinical 65 AIR CF1 65 Phase Ib study 65 randomized controlled 65 safety tolerability 65 multicenter randomized double 65 Phase Ib II 65 safety tolerability pharmacokinetic 65 blind placebo controlled 65 pivotal Phase 65 pharmacokinetic 65 multicenter randomized 65 pharmacokinetic PK 65 randomized 64 Phase Ib clinical trials 64 tolerated dose MTD 64 blinded randomized placebo controlled 64 double blinded placebo 64 Phase III 64 multicenter randomized placebo controlled 64 prospective multicenter 64 tolerability 64 Phase III randomized 64 Phase 2b 64 multicentre 64 pharmacokinetics 64 label multicenter 63 prospective randomized 63 Phase #/#a 63 dose cohorts 63 blinded placebo controlled 63 pharmacodynamics 63 placebo controlled randomized 63 blind randomized 63 multicenter clinical 63 controlled multicenter 63 BRIM2 63 randomized clinical 63 HGS ETR1 63 confirmatory Phase III 63 treatment naive genotype 63 viral kinetic 63 Phase III pivotal 63 AIR CF3 62 TMC# C# 62 oral deforolimus 62 Phase III clinical trials 62 Phase II 62 masked placebo controlled 62 registrational trial 62 RG# [001] 62 Phase #b/#a 62 dosing cohort 62 phase IIb study 62 INCB# [001] 62 pharmacodynamic PD 62 IIa clinical trial 62 multicenter prospective 62 Phase IIa trials 62 IMGN# 62 pharmacodynamic profile 62 Phase 1a clinical 61 prospective randomized controlled 61 evaluable patients 61 controlled dose escalation 61 randomized controlled Phase 61 multicentre randomized 61 pharmacokinetic PK study 61 relapsed refractory multiple myeloma 61 multicenter phase 61 ganetespib 61 pharmacokinetic profile 61 pharmacodynamic effects 61 axitinib 61 RDEA# 61 randomized #:# 61 refractory CLL 61 Phase 2b randomized 61 Phase 1b clinical trials 61 HCV SPRINT 61 placebo controlled Phase III 61 pertuzumab 61 multicenter randomized controlled 61 multicenter study 61 huC# DM4 61 AIR CF2 61 active comparator 60 registrational 60 dose cohort 60 alvespimycin 60 Phase IIIb clinical 60 oral ridaforolimus 60 randomized Phase IIb 60 ongoing Phase 1b 60 HER2 positive metastatic breast 60 double blinded randomized 60 prospective observational 60 ORMD 60 phase IIb trial 60 Blinatumomab 60 oral prodrug 60 Amrubicin 60 placebo controlled dose escalation 60 CR# vcMMAE 60 AEG# 60 nonrandomized 60 dosing cohorts 60 Phase IIIb 60 Allovectin 7 ® 60 multicentre randomized double 60 IMC A# 60 EOquin TM 60 Phase IIb clinical trials 60 docetaxel 60 pharmacokinetic studies 60 dose regimens 60 Enzastaurin 60 JAK inhibitor 60 ABSORB trial 60 Imprime PGG 60 multicenter placebo controlled 59 multicenter multinational 59 telaprevir dosed 59 lintuzumab 59 Sym# 59 ofatumumab 59 treatment naïve genotype 59 Sapacitabine 59 dose pharmacokinetic 59 administered subcutaneously 59 de novo kidney transplant 59 null responder HCV 59 PEG Interferon lambda 59 DLTs 59 mapatumumab 59 huN# DM1 59 dosing regimens 59 PXD# 59 Phase IIIb study 59 Cloretazine R VNP#M 59 histone deacetylase HDAC inhibitor 59 #mg QD [002] 59 PF # [001] 59 ADVANCE PD 59 tgAAC# 59 SCH # 59 nab paclitaxel 59 Phase III randomized controlled 59 Phase IIb trials 59 blind multicenter 59 docetaxel Taxotere R 59 glufosfamide 59 phase Ib clinical 59 prospective randomized placebo 59 Dacogen injection 59 bendamustine 59 PRECiSE 59 orally bioavailable 59 NGX# 59 PREZISTA r 59 CEQ# 59 blind placebo 59 randomized blinded 59 pharmacodynamics PD 59 SUCCEED trial 59 HGS# 59 HCD# [002] 59 randomized multicentre 59 Azedra 59 carboplatin paclitaxel 59 investigational compound 59 immunogenicity 59 gemcitabine 59 LUX Lung 59 dose limiting toxicities 59 Phase 58 IDX# 58 investigational oral 58 FOLOTYN ® 58 rALLy clinical trial 58 CIMZIA TM 58 Pharmacokinetics PK 58 prospective multicenter randomized 58 II Clinical Trial 58 ELACYT 58 dyskinesia PD LID 58 PRTX 58 randomized controlled clinical 58 crizotinib PF # 58 HCV infected 58 Perifosine 58 enzastaurin 58 PEG PAL 58 Phase #b/#a clinical 58 evaluating tivozanib 58 multicenter Phase III 58 low dose cytarabine 58 elotuzumab 58 Cloretazine 58 PDX pralatrexate 58 sorafenib Nexavar 58 vicriviroc 58 NOX E# 58 label multicenter randomized 58 symptomatic BPH 58 BRIM3 58 Phase III metastatic melanoma 58 celgosivir 58 Phase III trials 58 #mg/m# [001] 58 CLORETAZINE TM VNP#M 58 Carfilzomib 58 Pivotal Trial 58 elacytarabine 58 pomalidomide 58 assessing T DM1 58 anti leukemic 58 unblinded 58 orally dosed 58 DermaVir Patch 58 GAMMAGARD 58 Phase #b/#a trial 58 VICTOR E1 58 dosage regimens 58 TACI Ig 58 initiate Phase 58 pharmacokinetic parameters 58 forodesine 58 randomized multicenter trial 58 XIENCE V Stent System 57 IIa clinical 57 prospective randomized multicenter 57 blinded randomized 57 Zenvia Phase III 57 imetelstat 57 trastuzumab emtansine T DM1 57 prospectively defined 57 AP# [003] 57 perifosine 57 refractory multiple myeloma 57 CTA# Injection 57 dose placebo controlled 57 mertansine 57 RSD# oral 57 FAME Study 57 neratinib 57 Phase Ib IIa 57 sunitinib 57 seliciclib 57 polymerase inhibitor 57 cell lymphoma CTCL 57 GLP toxicology studies 57 tanespimycin 57 KRN# 57 mg/m2 dose 57 intermittent dosing 57 metastatic HRPC 57 CALGB 57 TG# [001] 57 ascending dose study 57 receptor tyrosine kinase inhibitor 57 Azixa 57 MEK inhibitor 57 dacarbazine 57 PDE4 inhibitor 57 OncoVEX GM CSF 57 LibiGel Phase III 57 APTIVUS r 57 posaconazole 57 blind randomized controlled 57 Phase 2b clinical trials 57 clinical trials 57 Phase III confirmatory 57 sorafenib Nexavar ® 57 ISIS # 57 BAY #-# 57 confirmatory Phase 3 57 dexpramipexole 57 noninferiority 57 subcutaneously administered 57 aflibercept 57 PS# [001] 57 tolerability pharmacokinetics 57 docetaxel chemotherapy 57 mg kg dose 57 pegylated interferon alfa 2a 57 HuMax EGFr 57 Parkinson disease levodopa induced 57 relapsed refractory 57 subanalysis 57 VNP#M 57 Denufosol 57 dose regimen 57 ENDEAVOR IV 57 adecatumumab 57 desvenlafaxine succinate 57 mcg dose 57 GRN#L 57 humanized anti 57 Phase IIB 57 Kinesin Spindle Protein KSP 57 mg dose 57 LEXIVA r 57 HCV RESPOND 2 57 GetGoal Phase III 57 XL# [003] 57 APTIVUS 57 Proxinium TM 57 Traficet EN 57 metastatic renal cell carcinoma 57 Phenoptin 57 label multicenter Phase 57 CYT# 57 stage IIIB 57 dacetuzumab 57 CCR5 antagonist 57 Omacetaxine 56 metastatic hormone refractory 56 mCRC 56 randomized controlled trial 56 Phase #/#a trial 56 Tanespimycin 56 MGd 56 PD LID 56 efavirenz EFV 56 virus HCV protease inhibitor 56 randomized Phase 2b 56 relapsing remitting multiple sclerosis 56 CA4P 56 generation PNP inhibitor 56 MGCD# [002] 56 REVIVE Diabetes 56 preclinical studies 56 R#/MEM # 56 Pralatrexate 56 albinterferon alfa 2b 56 #mg BID [001] 56 Ozarelix 56 Alocrest 56 REVLIMID lenalidomide 56 oral rivaroxaban 56 obatoclax 56 IL# PE#QQR 56 liposomal formulation 56 GSK# [001] 56 ADXS# 56 COU AA 56 retrospective observational study 56 CHAMPION PCI 56 pegylated interferon alpha 56 relapsed multiple myeloma 56 sunitinib malate 56 depsipeptide 56 #mg/m# [002] 56 pivotal bioequivalence 56 randomized placebo 56 COMFORT II 56 NCCTG 56 Fludara 56 Clinical Study 56 mcg kg 56 PEG SN# 56 recurrent NSCLC 56 velafermin 56 Phase III placebo controlled 56 capecitabine Xeloda R 56 AQ4N 56 perifosine KRX 56 ZACTIMA 56 GALNS 56 TMC# [002] 56 maximally tolerated dose 56 European Sepsis Trial 56 AeroLEF TM 56 plus prednisone 56 Vicinium TM 56 Augment Injectable 56 MAP# 56 resminostat 56 Hsp# Inhibitor 56 melphalan prednisone 56 leukemia CLL 56 kinase inhibitor 56 fosbretabulin 56 vinorelbine 56 randomized crossover 56 telaprevir dosing 56 investigational humanized monoclonal antibody 56 recurrent glioblastoma multiforme 56 dasatinib Sprycel ® 56 heavily pretreated 56 selective androgen receptor modulator 56 Prostate Lung Colorectal 56 ARIKACE 56 chemoradiotherapy 56 HuMax CD4 56 randomized controlled multicenter 56 Darusentan 56 recurrent metastatic 56 NOXAFIL Oral Suspension 56 Randomized Phase 56 blinatumomab 56 temozolomide 56 Debio 56 XL# XL# XL# 56 PSN# [002] 56 NLX P# 56 μg dose 56 evaluating Xcytrin 56 PROPEL 56 OMP #M# 56 ILLUMINATE 56 budesonide foam 56 TELCYTA 56 CLL8 56 BR.# 56 thymalfasin 56 sequential dose escalation 56 Capesaris 56 ATL# [001] 56 Phase III Clinical Trial 56 non inferiority 56 prospectively randomized 56 EDEMA3 56 EORTC 56 INSPIRE Trial Phase III 56 8mg/kg 56 galiximab 56 Maximum Tolerated Dose MTD 55 PSMA ADC 55 ToGA 55 carfilzomib 55 biologic therapy 55 Dose escalation 55 Randomized Double blind 55 teriflunomide 55 unblinding 55 Phase III multicenter 55 Amigal 55 Annamycin 55 antiviral activity 55 Initiated Phase 55 Microplasmin 55 PNP inhibitor 55 antitumor activity 55 phase IIIb 55 relapsed refractory AML 55 Alpharadin 55 bicifadine 55 deforolimus 55 trastuzumab Herceptin R 55 randomized multicenter Phase III 55 Folfox 55 systemic RNAi therapeutic 55 investigational drug 55 Ofatumumab 55 pharmacokinetic pharmacodynamic 55 T DM1 55 dirucotide 55 NO# [002] 55 thorough QT 55 Initiate Phase 55 PTH analogue 55 mg/m2 55 OncoVEX 55 cathepsin K inhibitor 55 dose escalation phase 55 comparator arm 55 ritonavir boosted 55 neoadjuvant 55 cilengitide 55 Archexin 55 relapsing multiple sclerosis 55 pharmacodynamic 55 Alzhemed TM 55 INCB# [002] 55 Fx #A 55 Bezielle 55 temsirolimus 55 MLN# 55 LEP ETU 55 subcutaneous formulation 55 Aflibercept 55 DU #b 55 fallopian tube cancers 55 sorafenib tablets 55 BLA submission 55 Cloretazine ® 55 CIMZIA TM certolizumab pegol 55 multicenter randomized Phase 55 paclitaxel poliglumex 55 AEGR 55 NP2 Enkephalin 55 HRPC 55 observer blinded randomized 55 monotherapy 55 TG MV 55 YONDELIS 55 peg IFN 55 OPT CHF 55 humanized monoclonal antibody 55 aflibercept VEGF Trap 55 intravenous dose 55 relapsed MM 55 lorvotuzumab mertansine 55 AEZS 55 Tyrima 55 nucleoside analog 55 peg interferon 55 Quinamed 55 CK # 55 denufosol 55 mCRC patients 55 standard chemotherapy regimen 55 KRAS mutations occur 55 REOLYSIN ® 55 Laquinimod 55 recurrent glioma 55 Cotara 55 lintuzumab SGN 55 recurrent malignant glioma 55 EFAPROXYN 55 REALITY Trial 55 Phase IIb Trial 55 Ophena TM 55 ISENTRESS 55 Peg IFN 55 mg BID 55 refractory chronic lymphocytic 55 HGS ETR2 55 MGCD# [001] 55 papillary renal cell carcinoma 55 Tarceva TM 55 pegylated liposomal doxorubicin 55 plus dexamethasone 55 mg/m2/day 55 RE SURGE 55 bevacizumab Avastin ® 55 TRO# 55 antibody MAb 55 QLT# 55 TPI ASM8 55 BCIRG 55 CCX# 55 plus Copegus R 55 sodium glucose cotransporter 55 FTY# 55 Phase III psoriasis 55 tolerability profile 55 ruxolitinib 55 analgesic efficacy 55 #mg QD [001] 55 Onrigin 55 Irinotecan 55 metastatic pancreatic 55 DURATION 55 GEM OS2 55 Tarvacin TM 55 Atu# 55 DAPT 55 tesmilifene 55 bavituximab 55 limiting toxicity DLT 55 PROPEL trial 55 generation purine nucleoside 55 erlotinib Tarceva ® 55 otelixizumab 55 confirmatory clinical 55 cetrorelix 55 mGluR5 NAM 55 Marqibo 55 intravenous bolus 55 elagolix 55 azacitidine 55 Omacetaxine mepesuccinate 55 Dapagliflozin 55 cutaneous T cell 55 GEM OS1 55 unique alkylating agent 55 Phase 1b dose escalation 55 IAP inhibitor 55 Pegasys ® 55 viral kinetics 55 PROSTVAC ® 55 ozarelix 55 leukemia AML 55 placebo controlled clinical trials 55 ALN TTR# 54 NSABP 54 atazanavir ritonavir 54 Aplidin 54 EOquin 54 Dose Ranging Study 54 OXi# 54 cetuximab Erbitux ® 54 Androxal TM 54 rNAPc2 54 pegylated interferon alfa 2b 54 severe oral mucositis 54 LCP Tacro 54 JAK2 inhibitor 54 PRX # 54 ABSORB clinical 54 FOLFOX 54 immunomodulatory therapy 54 riociguat 54 MabCampath 54 EVEREST II 54 MAGE A3 ASCI 54 Dose Escalation Study 54 HDAC Inhibitor 54 urocortin 2 54 teduglutide 54 stage IIIb IV 54 Multiple Ascending Dose 54 plus gemcitabine 54 syngeneic 54 solid tumors 54 evaluable 54 Board DSMB 54 Phase IIb III 54 OMP #R# 54 intra articular injection 54 preclinical efficacy 54 ACTEMRA 54 Elvitegravir 54 intravenous belinostat 54 cannabinor 54 systemically administered 54 bevirimat Study 54 ataluren 54 AKT inhibitor 54 hA# 54 SAR# [004] 54 CDK inhibitor 54 refractory NSCLC 54 romidepsin 54 placebo controlled studies 54 intravenous dosing 54 previously untreated follicular 54 relapsed APL 54 Luteinizing Hormone Releasing Hormone 54 Phase III Pivotal 54 daclizumab 54 ZYBRESTAT 54 ALN TTR 54 relapsed CLL 54 decitabine 54 ThermoDox ® 54 CTCE 54 chlorambucil 54 paclitaxel carboplatin 54 cytarabine 54 plus ribavirin 54 multi kinase inhibitor 54 HPTN 54 ThermoDox R 54 LCP AtorFen 54 MOTIVATE 54 REG2 54 satraplatin Phase 54 randomized #:#:# 54 HCV genotype 1 54 dexamethasone Decadron 54 WX UK1 54 DEB# 54 Allovectin 7 R 54 Xcytrin 54 refractory cutaneous T 54 sapacitabine 54 TYKERB 54 label dose titration 54 Urocidin 54 non nucleoside inhibitor 54 Triapine 54 Panzem R NCD 54 vorinostat 54 RSD# 54 OMS# 54 mRCC 54 oral COTI 54 LHRH receptor positive 54 CRx 54 designated HVTN 54 voreloxin 54 belinostat 54 plasma pharmacokinetics 54 AzaSite Plus 54 irbesartan 54 DAVANAT 54 metastatic CRPC 54 LEVADEX 54 vemurafenib 54 Phase IIa clinical trials 54 valopicitabine 54 dirucotide MBP# 54 CLARITY study 54 TAXUS ATLAS 54 Chemophase 54 RG# ITMN 54 DP b# 54 Deforolimus 54 phase III ACCLAIM 54 EZN 54 MEND CABG II 54 ocular hypertension 54 LBH# 54 superficial bladder cancer 54 PROMACTA 54 clinical pharmacology studies 54 goserelin 54 EMPHASIS HF trial 54 nucleotide analog 54 midstage trials 54 weekly subcutaneous injections 54 Pivotal Study 54 subcutaneous doses 54 AERAS-#/Crucell Ad# 54 IND enabling 54 gemcitabine Gemzar ® 54 eculizumab 54 clinical trials Multikine 54 APPRAISE 54 inhibitor RG# 54 NSABP B 54 Exherin TM 54 MVax 54 TMC# [001] 54 VEGF Trap 54 nitazoxanide 54 ribavirin RBV 54 registrational studies 54 oral formulation 54 #I TM# 54 subcutaneous injections 54 omega interferon 54 interferon alfa 54 imetelstat GRN#L 54 mg administered orally 54 Phase III Trial 54 novel histone deacetylase 54 ixabepilone 54 vandetanib 54 FOLFIRI 54 APOPTONE 54 multicenter dose escalation 54 biliary tract cancer 54 trial evaluating PRX# 54 intravenously administered 54 Ixempra 54 PLX PAD 54 investigational 54 pharmacodynamic profiles 54 mGluR5 negative 54 abiraterone acetate 54 ANA# 54 recurrent glioblastoma 54 protein kinase inhibitor 54 vitro studies 54 highly immunogenic 54 boosted protease inhibitor 54 IIa trials 54 XmAb# 54 AVADO 54 Pharmacokinetic 54 HDACi 54 docetaxel Taxotere ® 54 patients evaluable 54 factorial design 54 Actilon 54 rapid virologic response 54 gemcitabine carboplatin 54 trabectedin 54 estramustine 54 doxorubicin cyclophosphamide 54 q8h 54 MORAb 54 varespladib 54 subcutaneous SC 54 castration resistant prostate cancer 54 SUTENT 54 APEX PD 54 TG# [003] 53 subcutaneous dose 53 evaluable subjects 53 NRTI 53 ENESTnd 53 CCR5 mAb 53 myelofibrosis MF 53 RE LY ® 53 mCi 53 ANCHOR trial 53 BMS # 53 CB2 selective receptor agonist 53 Clinical Trial 53 Zerenex 53 multinational multicenter randomized 53 multiple myeloma MM 53 TLK# 53 PI3K/Akt pathway inhibitor 53 lead Aganocide compound 53 HGS ETR1 mapatumumab 53 Proellex TM 53 lomitapide 53 MEND CABG 53 prospective cohort 53 refractory AML 53 ELND# 53 eosinophilic asthma 53 basal bolus regimen 53 diabetic neuropathic pain 53 non nucleoside 53 hypoxia inducible factor 53 castrate resistant prostate cancer 53 registrational Phase 53 PMX # 53 chemotherapy docetaxel 53 SYMMETRY trial 53 Oral NKTR 53 rindopepimut 53 GFT# 53 generation Hsp# inhibitor 53 controlled multicenter Phase 53 adalimumab 53 ZYBRESTAT fosbretabulin 53 INCB# [003] 53 HspE7 53 pegylated interferon 53 daunorubicin 53 Randomized Phase II 53 Phase 2b Clinical Trial 53 PRESEPT 53 platinum refractory 53 Tamibarotene 53 Zenvia ™ 53 radiolabeled TM# 53 occlusion PAO 53 ACTEMRA TM 53 DB# [003] 53 Epoetin alfa 53 nucleoside reverse transcriptase inhibitor 53 lubiprostone 53 3 registrational trial 53 VA# [002] 53 IMA# 53 milatuzumab 53 Phase 2b Study 53 oral sapacitabine 53 Pivotal Phase III 53 metastatic castrate resistant 53 metastatic RCC 53 luteinizing hormone releasing 53 MYDICAR ® 53 primary endpoint 53 Preclinical studies 53 IRX 2 53 TBC# 53 mg/m2 cohort 53 recurrent GBM 53 Vascular Disrupting Agent 53 alkylating agent 53 REMUNE R 53 5 fluorouracil leucovorin 53 anticancer compound 53 refractory metastatic colorectal cancer 53 CAMMS# 53 HQK 53 MERLIN TIMI 53 GOUT 53 RRMS patients 53 painful diabetic neuropathy 53 acyclovir Lauriad R 53 neoadjuvant chemotherapy 53 specific CCR9 antagonist 53 CLL SLL 53 SPIRIT FIRST 53 patients oral indibulin 53 XL# XL# XL# XL# 53 multicenter randomized clinical 53 rHuPH# 53 IV bolus 53 refractory CTCL 53 mg qd 53 farletuzumab 53 ofatumumab HuMax CD# 53 Plicera 53 preclinically 53 safety tolerability pharmacodynamics 53 refractory indolent non 53 eltrombopag 53 NXL# 53 IMPACT DCM 53 ADAGIO study 53 IV metastatic melanoma 53 entinostat 53 custirsen 53 bortezomib Velcade R 53 HCV NS5B polymerase 53 Diamyd ® 53 cediranib 53 refractory acute myeloid 53 synthetic retinoid 53 clofarabine 53 B CLL 53 initiate Phase 1b 53 KRAS wild 53 cisplatin vinorelbine 53 NSCLC 53 initiate Phase IIb 53 Pegasys plus Copegus 53 zalutumumab 53 tremelimumab 53 Degarelix 53 NEO3 53 IMP# 53 CYC# 53 Placebo controlled 53 tumors GIST 53 vascular disrupting agent 53 Peginterferon 53 GLPG# 53 CLIRS trial 53 CTAP# Capsules 53 Fibrillex TM 53 hormone refractory prostate cancer 53 IIb clinical trial 53 advanced carcinoid 53 peginterferon alfa 2b 53 RE LY 53 AMD# [003] 53 bolus injection 53 rFVIIa 53 dosing schedules 53 subgroup analyzes 53 Seliciclib 53 RCW breast cancer 53 Aeroquin 53 dependent kinase inhibitor 53 selective modulator 53 lexidronam injection 53 lymphoma CTCL 53 refractory Hodgkin lymphoma 53 gadobutrol 53 HCV protease inhibitor 53 chronic HCV infection 53 fluoropyrimidine